| Bioactivity | Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289[1]. |
| In Vivo | 在 H292 异种移植瘤模型中，Laprituximab (J2898A) 的最低有效剂量为 3 mg/kg[1]。 |
| Name | Laprituximab |
| CAS | 1622327-38-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chittenden T D, et al. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Research, 2013, 73(8_Supplement): 5467-5467. |